Phreesia, Inc. logo PHR - Phreesia, Inc.

Price: -- -- | CONSENSUS: Buy DETAILS
STRONG
BUY
0
BUY 18
HOLD 7
SELL 0
STRONG
SELL
0
| PRICE TARGET: $12.17 DETAILS
HIGH: $16.00
LOW: $9.00
MEDIAN: $12.00
CONSENSUS: $12.17
UPSIDE: 2.83%
AlphaVal

AlphaVal

Deterministic, archetype-aware fair value

Platform & Compounding FCF 85% confidence

Primary model: Two-stage FCF DCF

Valuation Signal Overvalued Strong
Trading 163.4% above fair value
Current Price $11.84
Bear Case $4.25 64.1% downside ($4.25 - $11.84) / $11.84 = -64.1% 3% stage 1 growth, 11% discount
Fair Value $4.49 62.0% downside ($4.49 - $11.84) / $11.84 = -62.0% 4% stage 1 growth, 11% discount
Bull Case $4.91 58.5% downside ($4.91 - $11.84) / $11.84 = -58.5% 5% stage 1 growth, 11% discount

Adjust Assumptions

3.7%
11.0%
3.0%

Key Value Driver

FCF growth rate (4% base case)

Terminal Value % of EV 33%
Implied Market Multiple 33.6x
Market is pricing in (growth) 15.9% vs our 3.7% base

Plain-Language Summary

Using a two-stage FCF DCF with 4% growth decelerating over 15 years, discounted at 11%, the base-case intrinsic value is $4.49 per share.

Analyst Consensus (External Reference)

Never blended into the bear/base/bull estimates above -- shown only as an outside comparison.

Average Target (25 analysts) $12.17
Analyst Range $9.00 – $16.00
Divergence from AlphaVal 63%

Warnings

Stock-based employee pay equals 2925% of profits. This dilutes existing shareholders, so cash flow alone overstates what owners really earn.
Wall Street's average price target is $12.17 (from 25 analysts). Our estimate is 63% below the consensus -- consider that gap carefully.

Key Risks

  • P/E alone misleads — earnings depressed by growth investment
  • Cyclical or commodity businesses may be misclassified as platforms
  • Terminal value dominance suggests sensitivity to long-run assumptions